HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCS) AND USE IN THERAPY

The present invention relates to novel Histone Deacetylase Inhibitors (HDACi)- based antibody drug conjugates particularly with antibodies directed to ErbB1, ErbB2 and ErbB3 receptors, pharmaceutical compositions comprising said antibodies as well as to their use in the treatment of cancer or tumor...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	TADDEI, MAURIZIO, GIANNINI, GIUSEPPE, VESCI, LOREDANA, MILAZZO, FERDINANDO MARIA, FALTONI, VALENTINA, PETRICCI, ELENA, DE SANTIS, RITA
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to novel Histone Deacetylase Inhibitors (HDACi)- based antibody drug conjugates particularly with antibodies directed to ErbB1, ErbB2 and ErbB3 receptors, pharmaceutical compositions comprising said antibodies as well as to their use in the treatment of cancer or tumor and other diseases where a modulation of one or more histone deacetylase isoforms can be effective for therapeutic interventions. La présente invention concerne de nouveaux conjugués anticorps-médicaments à base d'inhibiteurs d'histone désacétylase (iHDAC), en particulier avec des anticorps dirigés contre les récepteurs ErbB1, ErbB2 et ErbB3, des compositions pharmaceutiques comprenant lesdits anticorps ainsi que leur utilisation dans le traitement du cancer ou d'une tumeur et d'autres maladies où une modulation d'une ou de plusieurs isoformes d'histone désacétylase peut être efficace pour des interventions thérapeutiques.